Skip to main content

ADC Therapeutics SA

ADCT
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001771910

No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding ADC Therapeutics SA changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of ADCT: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders3837−1
Shares34.0M34.7M+728.9K (+2.1%)
Value$56.4M$155.8M+$99.4M (+176.3%)

New holders (11)

Institutions that held ADC Therapeutics SA at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to ADCT in Q1 2024
InstitutionSharesValue% of portfolio
Adage Capital Partners GP, L.L.C.1,000,000$4.49M0.01%
Silverarc Capital Management, LLC501,222$2.25M0.63%
Monashee Investment Management LLC500,000$2.25M0.27%
Cubist Systematic Strategies, LLC120,775$542.3K0.01%
Sanibel Captiva Trust Company, Inc.103,000$462.5K0.02%
Two Sigma Investments, LP54,913$246.6K0.00%
D. E. Shaw & Co., Inc.26,921$120.9K0.00%
Balyasny Asset Management LLC23,765$106.7K0.00%
Aviso Wealth Management10,468$47.0K0.03%
Eagle Bay Advisors LLC670$3.01K0.00%
UBS Group AG51$2290.00%

Sold out (12)

Institutions that held ADC Therapeutics SA at the end of Q4 2023 and filed for Q1 2024 without it.